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Whether high total serum homocysteine levels (tHcy)
contribute to increase mortality or offer a survival advantage
in chronic hemodialysis patients remains controversial. We
conducted a prospective study to determine the impact of
tHcy on survival in this population with special respect to
chronic inflammation–malnutrition state (CIMS). In this
prospective study, 459 hemodialysis patients from 10 dialysis
centers located in two regions of France were included.
A number of baseline parameters were measured including
tHcy and markers of CIMS. Over a mean follow-up period of
54 months, 219 deaths (47.7%) occurred, of which 114 (52%)
were of cardiovascular (CV) origin. tHcy of equal to or greater
than 30 lmol/l was associated with a higher risk of all-cause
mortality in patients without CIMS (hazard ratio (HR): 1.55
(confidence interval (CI): 1.12–4.72)), but not in overall dialysis
population or those with CIMS. When only CV mortality was
considered, tHcy of equal to or greater than 30 lmol/l was
associated with a higher risk in patients without (CIMS
HR: 1.91 (CI: 1.23–3.23)), but not in those with CIMS.
Hyperhomocysteinemia is a strong risk factor for all-cause
and CV mortality in hemodialysis patients who do not
present CIMS. This association might be masked in patients
with CIMS.
Kidney International (2006) 69, 331–335. doi:10.1038/sj.ki.5000096
KEYWORDS: homocysteine; hemodialysis; cardiovascular; inflammation;
malnutrition
Dialysis patients present disproportionately high rates of
atherosclerotic events and cardiovascular (CV) mortality.1,2
A high prevalence of traditional and nontraditional CV risk
factors account for the increased incidence of atherosclerotic
complications in this population, although it seems difficult
to assess the relevance of each factor separately. As a
supplementary complication, a number of reports indicate
that, contrary to the general population, some CV risk factors
are strongly correlated with a decreased rate of cardiovascular
events (CVE) and death.3 Subsequently, a concept of ‘reverse
epidemiology’ has emerged to account for the inverse
association observed in dialysis patients between some so-
called traditional CV risk factors of the general population
and atherosclerotic disease.3
One of these factors is hyperhomocysteinemia (HHcy).
Indeed, although some initial epidemiologic studies4–9 have
found a strong association between HHcy and increased risk
of CVE and mortality in the dialysis population, a low total
serum homocysteine level (tHcy) has more recently been
reported to be a strong predictor of an elevated mortality risk
in dialysis patients.10–12 Nevertheless, even when these studies
are concordant and include large sample population size in
some cases, they are not exempt from bias and are unlikely to
reflect a causal relationship. Indeed, there is no theoretical
basis for an association between atherosclerosis and low tHcy
levels. Therefore, a reasonable doubt concerning this reverse
effect of HHcy in end-stage renal disease patients is allowed.
Especially, this paradoxical association may be due to a
confounding effect of inflammation and/or malnutrition,
which leads to lower homocysteine levels.
We conducted a prospective multicenter study to address
the role of HHcy on survival rate in hemodialysis population
with respect to other known CV risk factors, and to evaluate
whether the association between HHcy and mortality would
eventually be altered by the presence of a chronic inflamma-
tion–malnutrition syndrome (CIMS). In this study, we
included all patients on chronic hemodialysis in two regions
of France in a consecutive and unselected manner.
RESULTS
Demographic characteristics of the population
The demographic, clinical, and biological characteristics of
the study population are summarized in Table 1. Evidence of
CIMS was found in 49.8% (n¼ 228) of the patients. The
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presence of inflammation–malnutrition was associated with
lower body mass index and tHcy (Table 2).
Death
During a mean follow-up period of 54 months, 219 deaths
(47.7%) occurred, 126 in patients with CIMS and 93 in
patients without CIMS (114 (52%) of CVE, 65 in patients
with CIMS, and 49 in those without CIMS). Survival was
significantly lower in patients with CIMS (56 vs 40%;
Po0.001).
tHcy levels were not different in patients who died
during follow-up period in the overall cohort (29.178 vs
28.277.7 mmol/l; P¼ 0.12), but were higher in those without
CIMS (31.577.2 vs 26.476.8 mmol/l; P¼ 0.006). Of note, in
patients with CIMS, the association was in the opposite
direction: lower levels of tHcy were observed in patients who
died (24.677.2 vs 29.177.9; P¼ 0.01).
In the overall study population, univariate analysis
revealed that age (Po0.0001), male gender (P¼ 0.02), a past
history of CV disease (Po0.0001), smoking status (P¼ 0.11),
diabetes mellitus (P¼ 0.01), pulse blood pressure (BP) (P¼
0.03), C-reactive protein (CRP) (P¼ 0.0001), tHcy (P¼ 0.12),
and low albumin concentration (P¼ 0.008) were associated
with death.
Cox’s regression analysis showed that age in the higher
tertile (hazard ratio (HR), 3.33; 95% confidence interval (CI),
1.61–5.72) and previous history of CVE (HR, 2.12; 95% CI,
1.37–2.99) were risk factors for death. Diabetes mellitus also
increased the risk of death (HR, 1.68; 95% CI, 1.11–3.56) as well
as serum albumin concentration in the lowest tertile (Table 3).
Patients in the two higher tertiles of serum CRP level showed an
increased risk of death than those in the lowest tertile (Table 3).
tHcy was not associated with a significantly higher risk
of death in the overall population (Table 4). In contrast,
in the absence of CIMS, tHcy was positively associated with
all-cause mortality. In the full model, the adjusted relative
hazard of all-cause mortality associated with tHcy of greater
than 31 mmol/l was 1.55 (95% CI, 1.12–4.72) (Table 4).
However, in patients with CIMS, tHcy did not predict
subsequent death after full adjustment (Table 4), mostly
due to significant interaction between tHcy and CIMS
parameters.
Table 1 | Characteristics of the study population
Variable Mean Standard deviation Median
Age (years) 65 13 68
Male gender 62%
Current smoking 25%








PTH (pg/ml) 230 211 158
Hemoglobin (g/100 ml) 10.8 1.4 10.9
tHcy (mmol/l) 27.7 8 26
BMI (kg/m2) 24.2 4.2 23.9
Predialysis SBP (mmHg) 143 23 143
Predialysis DBP (mmHg) 76 12 76
Predialysis PP (mmHg) 67 17 67
Kt /V 1.47 0.33 1.43
nPCR 1.03 0.21 1.03
CRP (mg/l) 6.3 4.3 5
Serum albumin (g/l) 37 4.7 37
BMI, body mass index; CRP, C-reactive protein; DBP, diastolic blood pressure;
nPCR, protein catabolic rate; PP, pulse pressure; PTH, parathyroid hormone; SBP,
systolic blood pressure; tHcy, total serum homocysteine level.
Table 2 | Demographic, clinical and biological variables in





Age (years) 64714 66713 0.23
Male sex (%) 63 61 0.24




Diabetes mellitus (%) 18.4 22 0.19
Past history of CVD (%) 41 47 0.23
BMI (kg/m2) 25.674.8 22.873.9 0.03
Predialysis SBP (mmHg) 143723 145725 0.46
Predialysis DBP (mmHg) 76712 76713 0.49
Predialysis PP (mmHg) 67716 69717 0.37
Hemoglobin (g/100 ml) 10.971.4 10.671.4 0.19
PTH (pg/ml) 2227202 2587212 0.34
tHcy (mmol/l) 29.677.8 25.977 0.01
Kt /V 1.4870.30 1.5070.36 0.24
nPCR 1.0570.19 1.0170.25 0.11
CRP (mg/l) 4.672.4 974.8 o0.001
Serum albumin (g/l) 39.572.8 3474.5 o0.001
BMI, body mass index; CIMS, chronic inflammation–malnutrition state; CRP,
C-reactive protein; CVD, cardiovascular disease; DBP, diastolic blood pressure; nPCR,
protein catabolic rate; PP, pulse pressure; PTH, parathyroid hormone; SBP, systolic
blood pressure; tHcy, total serum homocysteine level.
Table 3 | Hazard ratio estimates for death derived from
proportional-hazards modeling (multivariate adjusted
model)
Variable Hazard ratio 95% CI P-value
CRP (mg/l)
o4 (1st tertile) 1 — —
[4; 8[ (vs 1st tertile) 1.78 [1.17; 3.56] 0.02
X8 (vs 1st tertile) 3.26 [1.78; 6.51] 0.002
Age (years)
o62 1 — —
[62; 72] 1.79 [0.96; 3.27] 0.07
X73 3.33 [1.61; 5.72] 0.002
Serum albumin (g/l)
o35 (1st tertile) 1 —
[35; 39[ (vs 1st tertile) 0.96 [0.86; 1.47] 0.272
X39 (vs 1st tertile) 0.81 [0.67; 0.91] 0.03
Diabetes mellitus
No 1 — —
Yes 1.68 [1.11–3.56] 0.01
History of CVE
No 1 — —
Yes 2.12 [1.37; 2.99] 0.006
CI, confidence interval; CRP, C-reactive protein; CVE, cadiovascular events.
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In assessing cause-specific mortality, we observed an
association between HHcy and CV mortality in the overall
population. This relationship was found to be significant in
patients without CIMS. In contrast, low tHcy concentrations
conferred a trend towards an increased risk of CV-related
mortality in patients with CIMS (Table 5).
DISCUSSION
Hemodialysis population presents a high rate of mortality
compared to the general population. In our patients, the
cumulative risk for death was found to be as high as 11%
within 1 year. CV deaths accounts for more than one-half of
deaths. A number of traditional and nontraditional risk
factors have been identified to be of higher prevalence in this
population potentially explaining this high rate of CV
mortality.
Although interventional studies have remained contra-
dictory,13,14 a large majority of epidemiologic studies have
reported a positive association between HHcy and CV disease
in the general population. However, conflicting reports exist
regarding the association between tHcy levels and mortality
in patients on chronic dialysis. Although some authors have
found that, similar to the general population, HHcy is
associated with an increased risk of CVE and mortality in
dialysis patients,4–9 others have reported an inverse relation-
ship in this population. The latter group found that dialysis
patients with higher tHcy manifested a better survival rate
than those with lower values. For instance, in a study on 117
hemodialysis patients, Suliman et al.10 found that those
patients with tHcy above the median (equal or greater than
24 mmol/l) showed a significantly lower 4-year survival rate
than those with lower tHcy. However, more recently,
Kalantar-Zadeh et al.11 also reported that mortality rate
was higher in the lowest tHcy quartile than in other quartiles.
In this study, the lowest tHcy quartile contributed to a
twofold increase in the risk of death. Wrone et al.12 reported
similar results in a prospective study on 510 chronic
hemodialysis patients. Moreover, in this study, tHcy-lowering
treatment did not reduce mortality maybe, at least in part,
because of a small effect of treatment on tHcy concentrations.
This paradoxical association puts under question the
usefulness of treatment with folic acid in dialysis patients.
Our data do not support this finding. In our study, we
demonstrate a strong, positive association of tHcy with
overall and CV mortality in dialysis patients who do not
present a chronic state of inflammation–malnutrition. In
contrast, we observed a trend towards an inverse relationship
between tHcy and all-cause and CV mortality in patients
with CIMS. These results indicate that, similar to the general
population, HHcy is a risk factor for all-cause and CV
mortality in dialysis patients, and that this association is
modified in individuals with CIMS. Consistent data indicate
that tHcy might be considered a nutritional and/or
inflammatory marker in dialysis patients.10 tHcy is lower in
patients with CIMS. A potential interaction between tHcy
and these parameters is likely to hamper our ability to detect
an independent role for HHcy on survival rate. tHcy results
could not then be accurately interpreted without taking into
consideration the presence or absence of CIMS.
The differences between results of our study and those
found by other authors could be explained by a number of
factors. Unlike most of other reports,11,12 our study
population did not suffer from a selection bias and included
the whole dialysis population in two regions, Bourgogne and
Franche-Comte´. Whether the phenotype of our study
population is different from that of other studies is difficult
to assess, but exclusion of some of the patients in those
studies might have changed or modulated their results. A bias
of survival may eventually explain, at least in part, the
paradoxical results of previous studies with the emerging
concept of ‘reverse epidemiology’. Incident patients with a
higher number of risk factors did not survive long enough to
be included in prospective studies or were excluded from the
study because of a too short life expectancy.11 Survival bias
can potentially exert a strong influence on both epidemio-
logic and clinical studies, especially when patients with
varying degrees of duration of dialysis are enrolled together.
In our study, dialysis duration was forced into the model to
persistently adjust our results for this confounding variable.
We analyzed the role of tHcy with respect to numerous
confounding factors including inflammatory (albumin, CRP)
and nutritional (albumin, normalized protein catabolism
ratio) parameters. In our opinion, considering the complex
interactions existing between tHcy and CIMS, these factors
cannot be analyzed separately. The difference in the frequency
of CIMS is another factor to be considered. Compared to
other studies, the proportion of patients with CIMS appears
low in our trial.15 The over-representation of this syndrome
in other studies may have contributed to the association
Table 5 | Hazard ratio estimates of tHcy for CV death derived







T1 (low) 1 1 1
T2 (medium) 1.16 [1.02; 1.35]* 0.95 [0.82; 1.08] 1.31 [1.00–3.11]
T3 (high) 1.51 [1.12; 1.72]* 0.90 [0.81; 1.01] 1.91 [1.23–3.23]*
CIMS, chronic inflammation–malnutrition state; T, tertile.
*o0.05.
Table 4 | Hazard ratio estimates of tHcy for death derived







T1 (low) 1 1 1
T2 (medium) 1.01 [0.76; 1.21] 0.91 [0.70; 1.03] 1.27 [0.97; 4.11]
T3 (high) 1.03 [0.82; 1.33] 0.78 [0.47; 1.02] 1.55 [1.12; 4.72]*
CIMS, chronic inflammation–malnutrition state; T, tertile.
*o0.05.
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found between low tHcy, a frequent feature of the CIMS, and
poor survival. Our study has a relatively longer follow-up
than the majority of studies reporting a ‘reverse epidemio-
logy’ effect. CIMS is the main cause of early death after
beginning the dialysis and short-term follow-up may have
accentuated the survival bias and the consequences of the
time–competition effect between risk factors, attenuating the
impact of traditional risk factors.
Our study suggests that the impact of HHcy is dependent
on the nutritional and inflammatory status. According to
the studied population, HHcy may appear as a protective
or deleterious factor. If a study population includes
predominantly healthy dialysis patients and has a long-term
follow-up, then the mortality–predictability of HHcy can be
seen in the same way as it is in the general population. If a
study population consists predominantly of malnourished
and inflamed patients, then HHcy is a marker of better
nutrition and is associated with better survival. Our study
reconciles the advocates of both conventional and reverse
epidemiology of tHcy in dialysis population. We showed
clearly that none of both parties are wrong or right, but it is
all about the confounding impact of malnutrition—inflam-
mation, which can be so dominant to the extent that it even
reverses such conventional associations. Our results also
suggest that tHcy-lowering trials in dialysis patients should
preferentially concern those without CIMS. Inclusion of
patients with CIMS may compromise any chance to observe a
significant impact of tHcy-lowering treatment in this
population.
There are some limitations to our study. We studied the
influence of a baseline tHcy and other factors on the
occurrence of death in a population of prevalent dialysis
patients. Serial measurements of these parameters in a
longitudinal cohort design would certainly provide a more
precise estimate of the risk in this population. Folate is one of
the major determinant of homocysteine. Folate status was
unknown and we cannot exclude both folate deficiency and
folic acid supplementation in some patients. Also, some
CV risk factors were not measured in our study, especially
lipid parameters, which may have potentially influenced
the results. Left ventricular hypertrophy was measured by
electrocardiogram, which is a less sensitive measure than
echocardiography. This may explain why left ventricular
hypertrophy was associated neither with all-cause nor CV
death. Finally, albumin is not only a nutritional marker
but also reflects the inflammatory status. In our study,
the presence of CIMS was defined as achievement of a priori
cutoffs for any of the two variables, CRP and albumin.
More accurate markers of malnutrition should probably be
used to assess the respective role of inflammation and
malnutrition. Nevertheless, the two entities are frequently
associated.
CONCLUSION
Our study demonstrates that tHcy must be interpreted with
caution in hemodialysis patients. Whereas low tHcy levels are
associated with poor prognosis in patients with the CIMS,
high tHcy levels independently predict death in patients
without the CIMS. The concept of reverse epidemiology is
probably only restricted to patients with the CIMS.
MATERIALS AND METHODS
Patients characteristics
Participants in the study were 459 chronic dialysis patients recruited
from 10 dialysis centers of Bourgogne (Dijon, Macon, Chalon sur
Saone, Auxerre, Sens) and Franche-Comte´ (Besanc¸on, Montbe´liard,
Vesoul, Dole). All stable patients on chronic hemodialysis with
dialysis duration of more than 3 months who showed no acute
illnesses were included.
Confounding factors
Age, gender, weight, size, blood pressure, hemodialysis duration,
weekly dialysis session duration, diabetes mellitus, smoking status,
past history of CVE and different biological parameters were
assessed upon inclusion.
Past history of CVE
A past history of CVE was defined by:
K Coronary heart disease: Myocardial infarction; coronary revascu-
larization including coronary artery bypass surgery or percu-
taneous transluminal coronary angioplasty; typical history of
angina with abnormal coronarography or myocardial scinti-
graphy.
K Stroke/cerebrovascular disease: Both hemorrhagic and non-
hemorrhagic strokes; carotid endarterectomy.
K Abdominal aortic or lower extremity arterial disease: Abdominal
aortic repair; lower extremity amputation; intermittent claudi-
cation confirmed by Doppler or arteriographic findings.
Nutritional status
Albumin concentration was determined. Body mass index was
calculated (weight/(size)2). Normalized protein catabolism ratio was
calculated.16
To distinguish individuals with any evidence of CIMS, a
composite variable combining serum albumin and CRP was used
to categorize the study population into two subgroups. The presence
of CIMS was defined as achievement of a priori cutoffs for any of the
two variables from previously reported studies.15 For serum albumin
levels, the cutoff was less than 36 g/l, and for CRP, it was 10 mg/l or
higher.
Smoking behavior
Subjects were categorized as current smokers or nonsmokers. A past
history of smoking was also assessed.
Blood pressure
BP was measured using a semiautomatic device, based on an
oscillometric method with the patients in a sitting position
after having rested for more than 5 min. Mean ðdiastolic BPþ
1
3ðsystolic BP  diastolic BPÞÞ and pulse pressure (systolic BPdiastolic
BP) were calculated.
Left ventricular hypertrophy
Left ventricular hypertrophy was defined by a Sokolow index equal
to or greater than 35.
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Residual renal function
Patients were categorized into two groups according to their daily
urine output (less than 500 ml, equal to or greater than 500 ml).
Parathyroid hormone
A past history of parathyroidectomy was assessed through medical
records. Intact parathyroid hormone (Elsa PTH, Scisbio, France)
was measured using an immunoradiometric assay, with a normal
range of 15–80 pg/ml.
Homocysteine
tHcy was measured using a previously described method.17 Venous
blood samples were drawn after an overnight fast. The blood sample
was centrifuged for 15 min, and plasma was stored frozen at 201C.
Hcy concentration, the sum of the acid-soluble (i.e. reduced Hcy,
homocysteine, disulfide, and homocysteine–cysteine mixed disulfide)
and protein-bound moieties were measured by high-performance
liquid chromatography. This assay involves the following steps:
reduction of the sample with tri-n-butylphosphine, precipitations of
proteins, alkalinization of the supernatant with sodium borate,
derivitization with 7-fluoro-2-oxa-1,3 diazole-4 sulfonate, followed
by 8-aminonaphthalene-1,3,6-trisulfonic acid, and high-performance
liquid chromatography separation with fluorescence detection.
The normal values of plasma Hcy concentration ranged from 7 to
15mmol/l. The precision of the assay corresponds to a coefficient of
variation of less than 3%.
C-reactive protein
CRP was measured by Nephelometry (Beckman, Palo Alto, CA, USA).
Death
Death from all causes was ascertained by active follow-up through
dialysis centers. The cause of death was considered to be CVE if it
was due to coronary heart disease, stroke or complicated peripheral
vascular disease. Sudden death was also counted in this group if a
past history of CVE existed.
Two physicians independent of the study and without the
knowledge of baseline characteristics were responsible for outcomes
ascertainment. This analysis was performed without the knowledge
of baseline characteristics.
Statistical analysis
Using log-rank tests on Kaplan–Meier nonparametric estimates of
the survival without death distribution, we selected variables with a
P-value lower than or equal to 0.20. All the variables depicted in
Table 1 were analyzed. The selected variables were included into a
Cox proportional-hazards model, and a backward stepwise selection
process was performed, this time at a classical a¼ 0.05. The time
elapsed as dialysis initiation was found to vary between patients;
therefore, this duration was forced into the Cox model as a
covariate. Cox’s proportional-hazards model was performed in the
overall study population, and further age was split into tertiles
(o64; 64–73; 473). Tobacco consumption was accounted for as
currently smoking vs nonsmoking. Variables split into tertiles were
replaced by dummy variables in the Cox model, which tested tertile
2 vs tertile 1 and tertile 3 vs tertile 1. Results are expressed as HR and
95% CI, with a P-value testing the null hypothesis: HR¼ 1.
Therefore, when P-value is less than 0.05, HR is significantly
different from 1, either greater than 1 (i.e. risk of death is increased)
or less than 1 (i.e. risk of death is decreased). Assumptions of Cox
models (log-linearity, proportionality of risk in time) were met in
this analysis.
Comparisons of the distribution of categorical variables between
patients with and without CIMS were performed by w2 tests, whereas
continuous variables were compared using the nonparametric
Wilcoxon’s rank-sum test.
Analyses were performed on statview 5 (SAS institute Inc., Cary,
NC, USA).
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